Table of Contents
What changed
Comvita delivered a sharp reversal in HY26, with revenue rising 18.3% to NZ$118.0m from NZ$99.7m in HY25, and NPAT swinging from a NZ$6.5m loss to a NZ$4.6m profit. PBT came in at NZ$4.3m; a small NZ$0.3m tax benefit lifted reported NPAT slightly above that, making PBT the cleaner operating read.
The most striking balance-sheet movement was inventory, which fell 43.4% to NZ$68.3m from NZ$120.8m in the prior comparable period — a reduction of NZ$52.5m. That inventory unwind was the primary engine behind operating cash flow of NZ$20.8m, which in turn reduced net debt from NZ$81.6m to NZ$48.7m. Gross borrowings fell NZ$36.2m to NZ$58.9m. Total assets shrank by NZ$143.5m to NZ$164.4m year-on-year, and total equity declined NZ$102.3m to NZ$58.3m — reflecting both prior-period impairments and the asset base reduction.
Trade receivables rose modestly to NZ$33.3m from NZ$31.0m, consistent with higher sales, but receivable days actually improved to 51.4 from 56.6. Capex was minimal at NZ$0.5m, or 0.4% of revenue. No dividend was declared.
What matters
-
Inventory unwind is doing the heavy lifting. The NZ$52.5m reduction in inventory drove both the operating cash flow result and the debt reduction. Inventory days fell from 220.5 to 105.5 — a normalisation that materially improves working capital optics, but which is largely a one-period phenomenon. The question is whether Comvita can sustain NZ$118m half-year revenue without rebuilding inventory significantly, or whether restocking pressure will emerge in H2 and FY27.
-
Revenue recovery is the strategic signal, but margin disclosure is absent. An 18.3% top-line increase after two consecutive years of revenue decline (FY25 revenue was 4% below the prior year, HY25 was 5% below) represents a genuine inflection. However, the filing provides no gross margin or EBITDA disclosure, so it is impossible to assess whether the revenue recovery translated into margin expansion or whether volume was bought at lower unit economics.
-
Leverage is improving but the balance sheet remains stretched. Net debt of NZ$48.7m against equity of NZ$58.3m leaves the gearing ratio elevated, and current borrowings of NZ$36.0m represent a near-term refinancing consideration. The debt trajectory is clearly improving, but covenant headroom and facility terms are undisclosed.
Expectations
No formal quantitative guidance or financial targets were disclosed in this filing. Contextual benchmarks must therefore come from the seasonal shape and the FY25 anchor.
In HY25, the first half contributed 51.8% of FY25 revenue and only 6.2% of the full-year NPAT result — the second half of FY25 produced a loss of NZ$98.3m, distorted by what appears to have been large impairments. Annualised HY26 revenue of NZ$235.9m would represent a 22.6% increase on FY25's NZ$192.4m, suggesting the current trading run-rate is materially ahead of last year.
The revenue recovery is ahead of any implied seasonal base. However, because the prior second half was dominated by non-operating write-downs rather than operating deterioration, the current period's operating profitability is not directly comparable to HY25 in isolation. What this result does support is that the operational restructuring — principally the inventory reduction and sales recovery — is proceeding. What it cannot yet support is a view on whether second-half revenue can hold at or near the first-half level, given the inventory position has normalised.
Quality of result
The profit turnaround has mixed quality characteristics. On the positive side, revenue growth of 18.3% is a genuine top-line recovery, and receivable days improved despite higher sales — a clean signal. The NZ$0.3m tax benefit is a minor flatter of NPAT relative to PBT, not a distorting item.
The more significant durability question is the inventory unwind. Operating cash flow of NZ$20.8m is approximately 4.4x NPAT, a ratio that strongly implies working capital release rather than earnings-backed conversion. When inventory normalises to a steady-state level, operating cash generation will need to be funded from genuine margin, not drawdown. With capex at just NZ$0.5m, the business is not investing meaningfully in growth assets, which could reflect disciplined capital allocation post-restructuring — or an inability to invest while managing debt. The absence of EBITDA or gross margin disclosure prevents a cleaner read on underlying operating leverage.
On balance, the earnings recovery has a solid revenue foundation, but the cash and debt improvement are substantially inventory-cycle driven and should not be extrapolated as run-rate cash generation.
Unresolved
- Gross margin and EBITDA are not disclosed, leaving the profitability of the revenue recovery unquantifiable. Did the 18.3% revenue increase come with margin expansion or compression?
- The NZ$36.0m of current borrowings raises a near-term refinancing question: what are the facility terms, maturity profile, and covenant positions?
- The inventory drawdown is the central driver of cash and debt improvement — what is management's intended steady-state inventory level, and does the supply chain support maintaining current revenue run-rates at lower stock holdings?
- Total equity fell NZ$102.3m year-on-year, a decline far exceeding the current period's operating results, implying prior impairments or write-downs. The composition and reversibility of those charges is not addressed in the available excerpts.
- Geographic or channel mix behind the revenue recovery is not disclosed, making it impossible to assess concentration risk or the sustainability of individual market contributions.
This briefing cannot assess whether Comvita's lender covenant thresholds are being met or whether the current borrowing facilities will be renewed on comparable terms.
Key metrics
| Metric | HY26 | HY25 | Change |
|---|---|---|---|
| Revenue | $118.0m | $99.7m | +18.3% ↑ |
| Net profit after tax | $4.6m | −$6.5m | +170.8% ↑ |
| Net cash inflow from operating activities | $20.8m | — | — |
| Cash and cash equivalents | $10.3m | $13.6m | -24.5% ↓ |
| Total assets | $164.4m | $307.9m | -46.6% ↓ |
Source: annolyse.ai/briefings/cvt-hy26
Analytical metrics
| Metric | HY26 | HY25 | Context |
|---|---|---|---|
| Effective tax rate | -7.4% | n/a | — |
| FCF pre-lease | $20.3m | — | — |
| FCF / NPAT | 441.6% | — | complementary conversion metric |
| Capex % revenue | -0.4% | — | — |
| Capex | −$0.5m | — | — |
| Debtor days | 51.4 | 56.6 | -5.2 days |
| Inventory days | 105.5 | 220.5 | -115.0 days |
| Trade debtors | $33.3m | $31.0m | +$2.3m |
| Net debt | $48.7m | $81.6m | −$32.9m |
| Gross borrowings | $58.9m | $95.2m | −$36.2m |
| Payout ratio vs NPAT | 0.0% | — | — |
| Payout ratio vs FCF pre-lease | 0.0% | — | covered |
| HY25 share of FY25 revenue | 51.8% | — | Other half was 48.2% |
| HY25 share of FY25 NPAT | 6.2% | — | Other half was 93.8% |
| Profit from continuing operations | $4.6m | −$6.5m | +$11.1m |
Source: annolyse.ai/briefings/cvt-hy26
This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.